FY2025 Earnings Estimate for ANRO Issued By Chardan Capital

Alto Neuroscience, Inc. (NYSE:ANRO) – Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Alto Neuroscience in a research report issued on Wednesday, November 19th. Chardan Capital analyst K. Nakae forecasts that the company will post earnings per share of ($2.45) for the year. Chardan Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Chardan Capital also issued estimates for Alto Neuroscience’s FY2026 earnings at ($1.80) EPS.

A number of other research analysts also recently issued reports on ANRO. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Robert W. Baird boosted their price target on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, October 8th. HC Wainwright lifted their price objective on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Finally, Jefferies Financial Group upped their target price on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $23.83.

Alto Neuroscience Price Performance

Shares of Alto Neuroscience stock opened at $13.32 on Monday. The business has a 50 day moving average of $8.96 and a 200 day moving average of $5.05. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $16.49. The company has a market cap of $413.85 million, a PE ratio of -5.82 and a beta of 2.81. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14.

Institutional Trading of Alto Neuroscience

Several hedge funds and other institutional investors have recently made changes to their positions in ANRO. Vanguard Personalized Indexing Management LLC raised its stake in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares during the last quarter. Peapod Lane Capital LLC grew its stake in shares of Alto Neuroscience by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after acquiring an additional 3,106 shares during the last quarter. Citizens Financial Group Inc. RI increased its holdings in shares of Alto Neuroscience by 19.0% during the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after acquiring an additional 6,394 shares in the last quarter. AlphaCore Capital LLC raised its position in shares of Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in Alto Neuroscience in the 2nd quarter worth about $25,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.